Bianca Hoeben discusses the latest guidelines from the SIOPE radiotherapy working group on vertebral radiotherapy dose in paediatric patients.

Anna Bibby joins The Lancet Oncology to discuss recent developments in the treament of malignant plural mesothelioma.

Frederick Locke joins The Lancet Oncology to discuss long-term results from the ZUMA-1 trial on the safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma.

Talía Malagón discusses her modelling study which assesses the age at which to stop cervical cancer screening in older women and the remaining lifetime risk of cervical cancer.

Stein Kaasa and Jon Loge discuss their new Commission on palliative care.

Andre Ilbawi talks about his global analysis of available national cancer control plans with The Lancet Oncology.

A review in The Lancet Oncology asks whether patient reported outcomes in RCTs are consistent across their analysis, reporting, and interpretation. Author Madeline Pe discusses the findings.

Eva Steliarova-Foucher joins The Lancet Oncology to discuss the Europe-wide Automated Childhood Cancer Information System, and the increase in cancer incidence rates among children and adolescents.

Mark Souweidane joins The Lancet Oncology to discuss his dose-escalation study, assessing a convection-enhanced delivery for diffuse intrinsic pontine glioma.

Bo Jan Noordman joins The Lancet Oncology to discuss the findings from his study of residual disease detection in oesophageal cancer.